The regulatory acceptance reinforces the cannabis company’s aspirations to be a leading player in the group.
Tilray (NASDAQ:TLRY) has started a new market for the own medical marijuana. The business announced Monday the Portugal’s national healthcare regulator, Infarmed, has given it permission to market its products from that nation.
“That is the first time a complete excellent dossier was demanded and sent to attain market authorization in Europe for a medical cannabis merchandise,” Tilray composed at the press release trumpeting the information.
– Read the whole post at The Motley Fool.